Effect of Epigallocatechin-3-Gallate on Graft-Versus-Host Disease

Cell Transplantation

Article

Edward D. Ziga¹  John F. Dipersio²  Matthew L. Cooper²  Julie Ritchey²  Jaebok Choi² 

[1] Division of Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA;Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA;

关键词: Graft-versus-host disease (GvHD);    Allogeneic hematopoietic stem cell transplantation (allo-HSCT);    Epigallocatechin-3-gallate (EGCG);    DNA methyltransferase 1 (DNMT1);    Interferon-γ receptor signaling;    Signal transducer and activator of transcription 1 (STAT1);   

DOI  :  10.3727/096368913X667691

 received in 2012-11-13, accepted in 2013-04-24,  发布年份 2014

来源: Sage Journals

【 摘 要 】

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often complicated by alloreactive donor T-cell-mediated graft-versus-host disease (GvHD). The major polyphenol of green tea, epigallocatechin-3-gallate (EGCG), is an inhibitor of both DNA methyltransferase 1 (DNMT1) and signal transducer and activator of transcription 1 (STAT1), which are essential for induction of GvHD. Thus, in this report, we examine if in vivo administration of EGCG mitigates GvHD in several different animal models. While we concede that refinement of EGCG treatment might result in GvHD prevention, our results suggest that EGCG treatment might not be an effective therapy against GvHD in the clinic.

【 授权许可】

Unknown   
© 2014 Cognizant Comm. Corp.

【 图 表 】

Figure 1